$75.15
0.98% yesterday
NYSE, Jun 13, 10:10 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$75.15
-0.35 0.46% 1M
+1.83 2.50% 6M
+1.12 1.51% YTD
-12.52 14.28% 1Y
+6.19 8.98% 5Y
+52.88 237.50% 10Y
+71.40 1,902.24% 20Y
NYSE, Closing price Fri, Jun 13 2025
-0.74 0.98%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Market capitalization $44.08b
Enterprise Value $40.78b
P/E (TTM) P/E ratio 10.57
EV/FCF (TTM) EV/FCF 65.45
EV/Sales (TTM) EV/Sales 7.36
P/S ratio (TTM) P/S ratio 7.96
P/B ratio (TTM) P/B ratio 4.35
Revenue growth (TTM) Revenue growth -6.00%
Revenue (TTM) Revenue $5.54b
EBIT (operating result TTM) EBIT $1.53b
Free Cash Flow (TTM) Free Cash Flow $623.10m
Cash position $3.90b
EPS (TTM) EPS $7.11
P/E forward 30.63
P/S forward 7.46
EV/Sales forward 6.90
Short interest 1.13%
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

16x Buy
50%
14x Hold
44%
2x Sell
6%

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

Buy
50%
Hold
44%
Sell
6%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5,539 5,539
6% 6%
100%
- Direct Costs 1,142 1,142
15% 15%
21%
4,397 4,397
3% 3%
79%
- Selling and Administrative Expenses 1,830 1,830
0% 0%
33%
- Research and Development Expense 1,052 1,052
2% 2%
19%
1,688 1,688
8% 8%
30%
- Depreciation and Amortization 153 153
3% 3%
3%
EBIT (Operating Income) EBIT 1,535 1,535
9% 9%
28%
Net Profit 4,181 4,181
196% 196%
75%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Positive
Seeking Alpha
10 days ago
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&...
Neutral
Investors Business Daily
17 days ago
Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.
Neutral
Business Wire
23 days ago
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptom...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today